PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...
A new study from the Italian Institute of Technology (IIT), in collaboration with Uppsala University (Sweden) and AstraZeneca, shows how computational chemistry and supercomputers can help scientists ...
Only two tracks have been made public, but you can start working on the Grammy trophy now. The best rock album of 2026 will ...
PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 ...
Intron retention is recognized as a key process in disease development, but its role in tuberculosis (TB) progression is ...
Patients with this genetic disorder have a form of dwarfism — they are short in stature and have underdeveloped ears and ...
Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global ...
Morning Overview on MSN
Study: RNA drugs work best when they reshape RNA, not just bind to it
Researchers led by Davide Incarnato at the University of Groningen have demonstrated that the FDA-approved cancer drug ...
PepGen Inc. PEPG shares are down during Tuesday’s premarket session following the announcement of topline results from the ...
Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global population infected with ...
Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is ...
The breaks at the Huntington’s Disease Therapeutics Conference are a great way to thaw out in CA’s February sunshine, take in the beautiful mountain views of Palm Springs, and network with ~450 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results